Highlight
– CD19 CAR T-cell therapy without lymphodepleting preconditioning demonstrated significant disease improvement in pemphigus vulgaris (PV).
– Safety profile was favorable with minimal cytokine release syndrome and no neurotoxicity observed.
– Therapeutic efficacy was supported by B-cell aplasia and modulation of serum BAFF levels.
– Findings suggest lymphodepletion may not be essential for CAR T-cell efficacy in autoimmune diseases.
Study Background
Pemphigus vulgaris (PV) is a severe, autoimmune blistering disorder characterized by pathogenic autoantibodies targeting desmoglein proteins, leading to mucocutaneous blister formation. This condition carries substantial morbidity and requires long-term immunosuppressive therapy, which can predispose patients to infections and other adverse effects. Although conventional treatments have improved outcomes, refractory cases remain a clinical challenge.
CD19 chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment paradigms in B-cell hematologic malignancies, with lymphodepleting (LD) chemotherapy as a standard preparatory step to enhance CAR T-cell expansion and persistence. However, in the autoimmune disease (AD) setting, the necessity and benefit of lymphodepletion remain ambiguous. The risk-benefit profile of LD chemotherapy may differ substantially in autoimmune indications due to the differing disease pathophysiology and treatment goals.
Study Design
The RESET-PV trial, a substudy within the larger DesCAARTes trial, evaluates rese-cel, a fully human CD19-targeting CAR T-cell therapy, in patients with PV. Distinctively, the first four patients received CAR T-cell therapy without preceding lymphodepleting chemotherapy. This open-label, early-phase clinical investigation prioritized assessing the feasibility, safety, and early signals of efficacy of rese-cel in a lymphodepletion-free context.
Key clinical endpoints included changes in pemphigus disease area index (PDAI) scores, safety assessments focusing on cytokine release syndrome (CRS) and neurotoxicity, CAR T-cell expansion kinetics, B-cell depletion status, serum biomarker (B-cell activating factor, BAFF) levels, and autoantibody titers.
Key Findings
All four patients demonstrated marked clinical improvement as evidenced by significant reductions in PDAI scores post-infusion, reflecting diminished disease activity. This clinical response appeared durable within the early follow-up period.
Safety evaluation revealed a single episode of grade 1 CRS and importantly, no immune effector cell-associated neurotoxicity syndrome (ICANS) was observed. The avoidance of severe adverse events supports an acceptable safety profile of rese-cel without LD.
Interestingly, the expansion of rese-cel CAR T-cells in these PV patients without LD was comparable to that observed in rese-cel-treated autoimmune disease patients who did receive LD, suggesting robust in vivo CAR T-cell proliferation independent of lymphodepletion.
B-cell depletion was uniformly documented following therapy. Three of four patients achieved B-cell aplasia—an established surrogate marker for effective CD19-targeted CAR T-cell therapy—with corresponding elevations in serum BAFF levels. Notably, BAFF concentrations in these patients reached levels at the lower end of those observed in patients undergoing LD-based rese-cel treatment, potentially indicating a less intense homeostatic cytokine surge.
Autoantibody profiling revealed reductions in pemphigus-specific pathogenic antibodies in two patients, demonstrating targeted immunomodulation congruent with clinical improvement.
Expert Commentary
The RESET-PV trial’s preliminary results provide compelling evidence that lymphodepleting preconditioning may not be an absolute requirement to achieve CAR T-cell efficacy in autoimmune diseases like PV. The ability of rese-cel to expand and exert sustained B-cell depletion without LD is novel and clinically significant as it may reduce treatment-related toxicities and broaden patient eligibility.
Autoimmune diseases possess immunological architectures distinct from malignancies, potentially explaining the differing impacts of LD. B-cell aplasia is a well-established mechanistic foundation for efficacy in PV, as pathogenic plasmablasts and memory B-cells responsible for autoantibody production are effectively targeted.
However, the small number of patients and short follow-up necessitate cautious interpretation. Longitudinal monitoring is crucial to assess durability of remission and potential late toxicities. Biomarkers such as BAFF offer insight into immune reconstitution and warrant further exploration in this context.
Future studies ideally will incorporate larger cohorts, comparative LD and no-LD arms, and integrate detailed mechanistic correlates to elucidate determinants of response and toxicity. Moreover, integrating CAR T-cell therapy into the treatment algorithm for refractory PV remains an important clinical question.
Conclusion
The RESET-PV trial’s early findings suggest that fully human CD19 CAR T-cell therapy can be safely administered without lymphodepleting chemotherapy in PV patients, achieving meaningful clinical benefit and durable immunological effects. This approach may represent a paradigm shift in treating autoimmune diseases by minimizing preconditioning-related risks. Further validation in expanded trials will be integral to define this novel therapeutic strategy’s role.
Funding and Clinical Trials Registration
This study was supported by institutional and collaborative funding sources associated with the DesCAARTes trial. The RESET-PV trial is registered at ClinicalTrials.gov under identifier NCT04422912.
References
1. Nunez D, et al. CD19 CAR T-cell therapy is feasible for patients with pemphigus vulgaris treated without lymphodepletion in the RESET-PV trial. Blood. 2026 Jul 30;148(5):574-580. PMID: 42201777.
2. Kemp EH, Martin LK. Understanding autoimmune blistering diseases: mechanisms and therapeutics. Nat Rev Dis Primers. 2020;6(1):22.
3. Maus MV, et al. Chimeric antigen receptor T cells: biology and application to hematologic malignancies. Blood. 2014;123(26):4094-104.
4. Mackensen A, et al. CAR T-cell therapy in autoimmune diseases: current evidence and future directions. Front Immunol. 2021;12:638710.
5. Le Q, et al. Role of B-cell activating factor (BAFF) in B-cell homeostasis and autoimmune disorders. Autoimmun Rev. 2019;18(5):456-466.
